GIPL vs IDXX vs BFLY Stock Comparison

Global Innovative Platforms, Idexx Laboratories and Butterfly Network Prices as of Oct 26, 2026 Peers: Industry group
BFLY Butterfly Network, Inc.
$7.40 -21.2% 1M +236.4% 1Y
Market cap
$2.03B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

8 decided of 12

Idexx Laboratories leads on 5 of the 12 questions below (Idexx Laboratories 5, Butterfly Network 2, Global Innovative Platforms 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGIPLIDXXBFLYLeader
Larger companyMarket capitalisation $24.88M $44.69B $2.03B IDXX
Cheaper on earningsLower P/E, profitable companies only -36.0x 39.2x -27.2x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 35.9x — –
Faster revenue growthRevenue growth, trailing twelve months — +12.8% +28.1% BFLY
More profitableNet margin, trailing twelve months -361.7% 25.0% -66.7% IDXX
Better return on capitalReturn on invested capital — 45.6% — –
Less leveragedLower net debt / EBITDA 0.4x 0.5x — GIPL
Higher dividend yieldTrailing dividend yield — 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -37.5% -13.3% +236.4% BFLY
Better 5-year returnAnnualised price return, 5 years -36.9%/yr -3.0%/yr -6.3%/yr IDXX
Less volatileAnnualised volatility, 1 year 271.4% 32.1% 114.8% IDXX
Higher overall scoreMean of the five percentile scores vs peers 55/100 77/100 45/100 IDXX

Percentile Scorecard

GIPLIDXXBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGIPLIDXXBFLY
Valuation 62 #241 of 625 75 #159 of 625 28 #164 of 227
Growth 27 #442 of 602 76 #148 of 602 68 #71 of 219
Profitability 39 #335 of 551 97 #18 of 551 32 #140 of 206
Financial Health 98 #12 of 656 47 #349 of 656 61 #94 of 238
Shareholder Returns 50 #183 of 365 93 #26 of 365 37 #85 of 134
Overall 55 77 45
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • IDXX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGIPLIDXXBFLYSPY
1 month 0.0%+8.1%-21.2% -0.2%
3 months 0.0%-1.5%+3.1% +3.9%
6 months -3.8%-1.2%+43.4% +8.2%
Year to date +354.5%-17.0%+94.7% +12.9%
1 year -37.5%-13.3%+236.4% +12.3%
3 years -52.4%+43.4%+836.7% +87.4%
3 years, per year -21.9%+12.8%+110.9% +23.3%
5 years -90.0%-14.1%-27.6% +67.9%
5 years, per year -36.9%-3.0%-6.3% +10.9%
10 years -82.9%+435.0%— +261.1%
10 years, per year -16.2%+18.3%— +13.7%

Risk

MeasureGIPLIDXXBFLYSPY
Volatility, 1Y 271.4%32.1%114.8% 12.7%
Downside volatility, 1Y —31.2%91.7% 12.7%
Beta vs S&P 500, 1Y 2.270.793.00 1.00
Return / volatility, 1Y -0.14-0.412.06 0.97
Max drawdown, 5Y -98.0%-51.3%-93.4% -25.4%
From 52-week high -49.5%-26.8%-25.6% -1.2%
52-week high $0.99$766.68$9.94 $779.14
52-week low $0.11$504.70$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGIPLIDXXBFLY
P/E now vs peer median -36.0xmedian 17.2x 38.9xmedian 17.2x -25.9xmedian 29.6x
P/S now vs peer median 132.9xmedian 9.0x 9.7xmedian 9.0x 15.7xmedian 2.9x
EV/EBITDA now vs peer median -39.5xmedian 16.3x 27.9xmedian 16.3x -22.6xmedian 17.4x
P/FCF now vs peer median -32.5xmedian 18.7x 35.3xmedian 18.7x -62.8xmedian 22.3x
P/B now vs peer median 46.8xmedian 2.2x 27.5xmedian 2.2x 9.3xmedian 2.3x
PEG now vs peer median -0.57median 0.33 2.58median 0.33 -0.96median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGIPLIDXXBFLY
Revenue $187.20K $4.55B $112.15M
Gross profit – $2.84B $59.04M
Operating income -$677.04K $1.46B -$79.38M
Net income -$677.04K $1.14B -$74.85M
Free cash flow -$766.04K $1.25B -$28.04M
R&D $377.99K $261.47M $38.10M
EPS (diluted) $-0.02 $14.37 $-0.29
Cash & equivalents $244.24K $196.93M $124.66M
Total debt $8.62K $968.86M –
Shares (diluted) 44.54M 79.31M 262.10M
Enterprise value $24.27M $43.91B $1.48B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGIPLIDXXBFLY
P/E -36.0x 38.9x -25.9x
P/FCF -32.5x 35.3x -62.8x
P/Operating cash flow -35.0x 32.3x -73.3x
P/S 132.9x 9.7x 15.7x
P/B 46.8x 27.5x 9.3x
P/Tangible book 47.1x 29.2x 9.6x
EV/EBITDA -39.5x 27.9x -22.6x
EV/EBIT -36.4x 30.9x -20.6x
EV/Revenue 131.6x 9.9x 14.6x
EV/FCF -32.2x 35.9x -58.4x
EV/Operating cash flow -34.7x 32.8x -68.1x
PEG (3Y EPS CAGR) -0.57 2.58 -0.96

Growth

14 metrics
MetricGIPLIDXXBFLY
Revenue growth (1Y) – 12.8% 28.1%
Revenue CAGR (3Y) – 9.0% 15.6%
Gross profit growth (1Y) – 14.4% 8.8%
Gross profit CAGR (3Y) – 10.5% 13.3%
Operating income growth (1Y) -20.9% 16.2% -14.8%
Operating income CAGR (3Y) -51.6% 11.7% 21.1%
Net income growth (1Y) -20.9% 15.6% -19.1%
Net income CAGR (3Y) -51.6% 12.9% 20.8%
EPS growth (1Y) -9.8% 18.1% -12.9%
EPS CAGR (3Y) 63.5% 15.1% 27.0%
Operating cash flow growth (1Y) 15.8% 51.4% 19.6%
Operating cash flow CAGR (3Y) -96.8% 22.5% 44.5%
Free cash flow growth (1Y) 9.2% 59.9% 12.2%
Free cash flow CAGR (3Y) -101.8% 28.4% 42.8%

Profitability

14 metrics
MetricGIPLIDXXBFLY
Gross margin – 62.4% 52.6%
EBITDA margin -333.4% 35.4% -64.4%
Operating margin -361.7% 32.0% -70.8%
Pretax margin -361.7% 31.3% -66.7%
Net margin -361.7% 25.0% -66.7%
FCF margin -409.2% 27.5% -25.0%
Operating cash flow margin -379.8% 30.1% -21.4%
Return on equity -120.8% 71.9% -39.3%
Return on assets -119.7% 33.4% -26.3%
Return on invested capital – 45.6% –
Return on capital employed -121.4% 68.6% -35.1%
Asset turnover 0.3x 1.3x 0.4x
Cash conversion (OCF / net income) 1.1x 1.2x 0.3x
Stock comp / revenue – 1.4% 21.3%

Financial Health

11 metrics
MetricGIPLIDXXBFLY
Debt / assets 1.0% 28.1% –
Debt / equity 0.0x 0.6x –
Net debt / EBITDA 0.4x 0.5x –
Debt / FCF 0.0x 0.8x –
Liabilities / assets 1.4% 53.2% 33.1%
Equity / assets 98.6% 46.8% 66.9%
Interest coverage – 38.6x -59.4x
Current ratio 34.7x 1.2x 4.1x
Quick ratio 33.2x 0.7x 2.7x
Cash ratio 31.3x 0.2x 2.1x
Altman Z-score 1,908 20.16 7.05

Shareholder Returns

7 metrics
MetricGIPLIDXXBFLY
Dividend yield – – –
Net buyback yield -3.2% 2.4% -0.4%
Shareholder yield -3.2% 2.4% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGIPLIDXXBFLY
Forward P/E – 35.9xFY2026 –
EPS, next fiscal year – $15.63FY2026 $-0.10FY2026
EPS growth, next FY – +19.5%FY2026 –
EPS growth, the year after – +12.9% –
Revenue, next fiscal year – $5.00BFY2026 $114.50MFY2026
Revenue growth, next FY – +16.3%FY2026 +17.3%FY2026
Revenue growth, the year after – +0.6% +26.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGIPLIDXXBFLY
Held by institutions – 93.6% 59.9%
Institutions holding – 1,289 245
Change in shares held, QoQ – +4.1% +13.9%
Institutions buying – 587 143
Institutions selling – 496 59
Buyers to sellers – 1.18 2.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GIPLIDXXBFLY
GIPL 1.00 0.06 0.01
IDXX 0.06 1.00 0.28
BFLY 0.01 0.28 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GIPL, IDXX and BFLY?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Global Innovative Platforms (GIPL) $24.88M, Idexx Laboratories (IDXX) $44.69B, Butterfly Network (BFLY) $2.03B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +12.8%, Butterfly Network (BFLY) +28.1%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Global Innovative Platforms (GIPL) -361.7%, Idexx Laboratories (IDXX) 25.0%, Butterfly Network (BFLY) -66.7%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Global Innovative Platforms (GIPL) -37.5%, Idexx Laboratories (IDXX) -13.3%, Butterfly Network (BFLY) +236.4%. Over five years, Idexx Laboratories (IDXX) compounded fastest (Global Innovative Platforms (GIPL) -36.9%/yr, Idexx Laboratories (IDXX) -3.0%/yr, Butterfly Network (BFLY) -6.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Global Innovative Platforms (GIPL) 271.4%, Idexx Laboratories (IDXX) 32.1%, Butterfly Network (BFLY) 114.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GIPL, IDXX and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.